Immunocore

Immunocore Holdings plc describes itself as a commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy. Its mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases by pioneering and delivering transformative immunomodulating medicines. Built on its proprietary ImmTAX platform, it reports a diverse pipeline of bispecific therapies across a broad range of indications, including multiple cancers, HIV and HBV. The company states that its science is based on research from the University of Oxford in the 1990s, and that in 2022 it launched the world's first TCR therapy. It also reports partnerships past and present including Genentech, GSK, and the Bill & Melinda Gates Foundation.

Immunocore states that its science is based on research from the University of Oxford in the 1990s, and that it developed a wholly-proprietary technology platform called Immune Mobilizing Monoclonal TCRs Against X disease (ImmTAX). The company says that based on this technology, in 2022 it launched the world's first TCR therapy. It describes itself as a commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved T cell receptor (TCR) therapy. It also reports a history of creating value through partnerships with industry, academia and the charitable sector, with partners past and present including Genentech, GSK, and the Bill & Melinda Gates Foundation.

• 2022.01.26

  Reported2022.01.26

  FDA approves Kimmtrak for certain patients with uveal melanoma[5]FDA 批准 Kimmtrak 用于部分葡萄膜黑色素瘤患者healio.com

  The FDA approved tebentafusp-tebn, marketed as Kimmtrak by Immunocore, for adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. The article describes it as the first T-cell receptor therapeutic to receive regulatory approval.

• 2021.02.09

  Reported2021.02.09

  Immunocore completes $15 million concurrent private placement[6]Immunocore完成1,500万美元同步私募配售finanznachrichten.de

  Immunocore announced completion of a private placement to the Bill & Melinda Gates Foundation, selling 576,923 ADSs at the IPO price for approximately $15 million in gross proceeds.

• 2021.02.04

  Reported2021.02.05

  Immunocore announces pricing of upsized IPO[7]Immunocore 宣布扩大规模的首次公开募股定价finanznachrichten.de

  Immunocore announced pricing of its upsized US IPO: 9,935,896 American Depositary Shares at $26.00 each, for approximately $258.3 million in gross proceeds. The shares were expected to begin trading on Nasdaq on February 5, 2021, and the offering was expected to close on or about February 9, subject to customary conditions.

• 2020.05.06

  Reported2020.05.06

  Immunocore appoints Brian Di Donato as CFO and Head of Strategy[8]Immunocore任命Brian Di Donato为首席财务官兼战略主管uk.finance.yahoo.com

  Immunocore appointed Brian Di Donato as Chief Financial Officer and Head of Strategy, effective immediately.

Read more

1. 1Immunocore Holdings plc (IMCR)immunocore.com
2. 2About Us :: Immunocore Holdings plc (IMCR)immunocore.com
3. 3Management Team :: Immunocore Holdings plc (IMCR)immunocore.com
4. 4Board of Directors :: Immunocore Holdings plc (IMCR)immunocore.com
5. 5FDA 批准 Kimmtrak 用于部分葡萄膜黑色素瘤患者healio.com
6. 6Immunocore完成1,500万美元同步私募配售finanznachrichten.de
7. 7Immunocore 宣布扩大规模的首次公开募股定价finanznachrichten.de
8. 8Immunocore任命Brian Di Donato为首席财务官兼战略主管uk.finance.yahoo.com
9. 9Immunocore Limited: Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategyfinanznachrichten.de